Showing 261-270 of 1743 results for "".
A Precision Medicine Approach to Dementia Care: Syndrome, Etiology, and Copathology
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/a-precision-medicine-approach-to-dementia-care-syndrome-etiology-and-copathology/32011/Recognizing multiple neuropathological entities in people with dementia improves understanding of diagnosis, prognosis, and expected outcomes from therapies.COVID-19 & Stroke
https://practicalneurology.com/diseases-diagnoses/stroke/covid-19-stroke/31740/COVID-19 has brought significant changes in stroke presentations, systems of care, and resource availability.Unraveling the Impact of Environmental Factors on Sleep Quality and Parkinson Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/unraveling-the-impact-of-environmental-factors-on-sleep-quality-and-parkinson-disease/32197/A review of the effects of various environmental factors—extreme temperatures, air and noise pollution, chemical exposures, and heavy metals—on both sleep and Parkinson disease.Patient-Reported Outcome Measures in Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/patient-reported-outcome-measures-in-neuromuscular-disorders/35531/Information gleaned from patient-reported outcome measures provides valuable insights into the effects of neuromuscular disorders on function and quality of life.- Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Fundinghttps://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosishttps://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (